Sun Pharma Signs a License Agreement with Rockwell Medical for Triferic in India
Shots:
- Rockwell to receive up front- milestones and royalties on sales of Triferic. Sun Pharma to get an exclusive right to develop & commercialize Triferic- following its approval in India
- Sun Pharma will be responsible for all clinical- regulatory and commercialization activities of Triferic in India. The collaboration allows Sun Pharma to expand its portfolio in its core therapy areas
- Rockwell's Triferic is a US FDA approved therapy indicated to replace iron and maintain hemoglobin in hemodialysis patients via dialysate during each dialysis treatment
Click here to read full press release/ article | Ref: Sun Pharma | Image: Behance
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com